Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT01628913 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
62
Enrollment
INDUSTRY
Sponsor class

Stopped This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals